Your browser is no longer supported. Please, upgrade your browser.
Progenity, Inc.
Index- P/E- EPS (ttm)-3.46 Insider Own11.20% Shs Outstand63.94M Perf Week38.32%
Market Cap360.11M Forward P/E- EPS next Y-1.01 Insider Trans118.90% Shs Float- Perf Month210.14%
Income-181.50M PEG- EPS next Q-0.45 Inst Own65.30% Short Float- Perf Quarter15.62%
Sales40.80M P/S8.83 EPS this Y-38.30% Inst Trans95.08% Short Ratio0.24 Perf Half Y-5.73%
Book/sh-2.18 P/B- EPS next Y66.80% ROA-178.60% Target Price6.00 Perf Year-62.05%
Cash/sh0.54 P/C5.46 EPS next 5Y- ROE215.80% 52W Range0.66 - 8.24 Perf YTD-44.26%
Dividend- P/FCF- EPS past 5Y- ROI-285.10% 52W High-64.08% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin-10.20% 52W Low350.53% ATR0.43
Employees511 Current Ratio1.30 Sales Q/Q-97.10% Oper. Margin- RSI (14)69.49 Volatility29.62% 25.27%
OptionableYes Debt/Eq- EPS Q/Q43.20% Profit Margin- Rel Volume4.09 Prev Close2.50
ShortableNo LT Debt/Eq- EarningsAug 12 AMC Payout- Avg Volume45.30M Price2.96
Recom2.20 SMA2065.09% SMA50117.94% SMA200-9.26% Volume185,251,689 Change18.40%
Oct-14-21Initiated H.C. Wainwright Buy $4
Jun-03-21Downgrade Robert W. Baird Outperform → Neutral $4 → $2
Feb-08-21Downgrade Wells Fargo Overweight → Underweight $11 → $5
Oct-23-20Initiated BTIG Research Buy $12
Jul-14-20Initiated Wells Fargo Overweight $11
Jul-14-20Initiated Robert W. Baird Outperform $12
Jul-14-20Initiated Raymond James Outperform $15
Jul-14-20Initiated Piper Sandler Overweight $17
Oct-22-21 05:27PM  
Oct-19-21 07:30AM  
Oct-18-21 10:06AM  
Oct-13-21 11:08AM  
Oct-12-21 03:50PM  
Oct-07-21 08:30AM  
Oct-06-21 04:02PM  
Oct-04-21 01:40PM  
Oct-01-21 12:46PM  
Sep-30-21 12:09PM  
Sep-21-21 07:30AM  
Sep-14-21 10:41AM  
Sep-03-21 07:30AM  
Aug-24-21 04:05PM  
Aug-23-21 08:30AM  
Aug-20-21 02:27PM  
Aug-19-21 10:20PM  
Aug-13-21 12:30AM  
Aug-12-21 05:35PM  
Aug-05-21 04:05PM  
Jul-31-21 09:06AM  
Jul-29-21 07:30AM  
Jul-06-21 07:10AM  
Jun-30-21 07:30AM  
Jun-25-21 10:50PM  
Jun-19-21 03:00AM  
Jun-17-21 07:30AM  
Jun-15-21 08:30AM  
Jun-11-21 10:50PM  
Jun-10-21 07:30AM  
Jun-02-21 07:00AM  
May-26-21 07:30AM  
May-25-21 07:30AM  
May-24-21 07:30AM  
May-21-21 07:30AM  
May-14-21 01:00AM  
May-13-21 04:03PM  
May-12-21 07:29AM  
May-11-21 03:30PM  
May-06-21 07:30AM  
May-05-21 07:30AM  
May-04-21 07:30AM  
Apr-30-21 04:04PM  
Apr-26-21 07:30AM  
Apr-08-21 07:30AM  
Apr-06-21 09:44AM  
Mar-27-21 09:58AM  
Mar-23-21 07:10AM  
Mar-20-21 05:06AM  
Mar-19-21 02:22PM  
Mar-18-21 04:05PM  
Mar-14-21 10:43PM  
Mar-12-21 07:30AM  
Mar-10-21 09:48PM  
Mar-09-21 10:09AM  
Mar-07-21 01:37PM  
Mar-03-21 03:10AM  
Feb-23-21 01:32PM  
Feb-22-21 02:22PM  
Feb-20-21 06:15PM  
Feb-19-21 12:25AM  
Feb-17-21 07:30AM  
Feb-15-21 09:53PM  
Feb-13-21 03:00PM  
Feb-12-21 07:30AM  
Feb-11-21 01:47PM  
Feb-10-21 07:30AM  
Feb-08-21 07:00AM  
Jan-20-21 07:30AM  
Jan-13-21 04:05PM  
Jan-05-21 07:30AM  
Dec-17-20 07:30AM  
Dec-09-20 12:50AM  
Dec-08-20 07:31AM  
Dec-07-20 02:52PM  
Dec-02-20 11:51PM  
Nov-30-20 09:39PM  
Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. It offers Innatal, a noninvasive prenatal screening test offered to women early in pregnancy to screen for chromosome abnormalities, such as down syndrome, trisomy 18, trisomy 13, and sex chromosome disorders through the analysis of cell-free DNA; Preparent that screens for carrier status of hereditary diseases prior to or early in pregnancy; and Riscover, a hereditary cancer screen that analyzes 31 genes associated with inherited risk of 12 types of cancers, including the BRCA1/2 genes for hereditary breast, ovarian, colorectal, endometrial, pancreatic, and other cancer syndromes, as well as for the five genes associated with Lynch syndrome. The company also provides Resura, a noninvasive prenatal test for families at risk for rare single gene disorders; and Preecludia, a preeclampsia rule-out test. In addition, it offers anatomic and molecular pathology tests, and COVID-19 PCR testing services, as well as test products that includes chromosomal microarray for pregnancy loss, which evaluates the genetic cause of miscarriage; maternal serum screening for chromosomal disorders; and preimplantation genetic testing for use with artificial reproductive technologies. Further, the company develops therapeutic solutions for gastrointestinal-related disorders, such as PGN-001, PGN-300, PGN-600, and PGN-OB2. It also owns and operates laboratory. Progenity, Inc. was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Athyrium Capital Management, L10% OwnerJun 14Buy2.478,097,16620,000,00036,396,907Jun 14 05:17 PM
Athyrium Opportunities Fund (A10% OwnerJun 14Buy2.478,097,16620,000,00036,396,907Jun 14 05:14 PM
Athyrium Opportunities Fund (A10% OwnerJun 01Buy2.861,268,1153,626,80928,299,741Jun 03 04:46 PM
Athyrium Capital Management, L10% OwnerJun 01Buy2.861,268,1153,626,80928,299,741Jun 03 04:41 PM
Silvestry DamonChief Operating OfficerDec 16Buy4.5858,081265,857221,230Dec 17 04:30 PM
Silvestry DamonChief Operating OfficerDec 15Buy4.0763,870259,951163,149Dec 16 04:26 PM
Alter Jeffrey D.DirectorDec 14Buy4.8520,00097,00038,335Dec 15 07:27 PM
Athyrium Opportunities Fund (A10% OwnerDec 07Buy3.274,128,44013,499,99926,991,626Dec 09 05:35 PM
Athyrium Capital Management, L10% OwnerDec 07Buy3.274,128,44013,499,99926,991,626Dec 09 05:35 PM
Stylli HarryChairman & CEODec 02Buy3.27152,905499,99914,616,874Dec 04 04:30 PM